Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's 40th Annual Meeting Life Science Investing
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis , Offering Alkaline Phosphatase Reduction, Itch Relief and Potential to Slow Disease Progression Life Science Investing
Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025 Medical Device Investing
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update Pharmaceutical Investing
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights Life Science Investing
